GHRP-6 vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHRP-6
Growth Hormone Releasing Peptide 6 (GHRP-6) is one of the first synthetic growth hormone secretagogues discovered. It stimulates significant GH release but is known for causing intense hunger.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | GHRP-6 | Teriparatide |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 20 mcg |
| Frequency | 3x daily | 1x daily |
| Cycle Length | 8–12 weeks | 52–104 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Acts as a ghrelin mimetic, binding to the GHS-R receptor in the pituitary and hypothalamus. Stimulates GH release and also significantly increases appetite by mimicking ghrelin's hunger-signaling effects. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily. Often combined with GHRH peptides like CJC-1295 for synergistic effects. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Subcutaneous injection. Best administered on an empty stomach. The strong hunger response can be beneficial for those trying to gain weight but challenging for cutting. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Intense hunger (most notable effect), water retention, increased cortisol and prolactin, tingling/numbness, and potential blood pressure changes. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
GHRP-6, Teriparatide are both commonly used for:
Key Differences
Unique to GHRP-6:
Which Has Stronger Evidence?
- Recovery & Healing: Teriparatide has stronger research support.
| Goal | GHRP-6 | Teriparatide |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
GHRP-6
- Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
Journal of nanobiotechnology, 2025
- Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.
Frontiers in pharmacology, 2024
- [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.
Molecular and cellular endocrinology, 2015
Teriparatide
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.
JAMA, 2026
- The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis.
The Journal of clinical endocrinology and metabolism, 2025
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.
Journal of bone and mineral metabolism, 2025
Ready to Learn More?
Looking for trusted sources?